Fast Tracked Client Reviews 2026 Fast Tracked means the FDA will engage more frequently through meetings at pre-IND, End of Phase 1, End of Phase 2, and pre-NDA/BLA stages, and those meetings under the Fast Tracked designation are not just perfunctory checkpoints but opportunities to resolve pivotal study design questions, discuss surrogate endpoints, and align on clinical endpoints that can satisfy approval requirements; because Fast Tracked encourages written communications too, sponsors get more documented guidance on data collection and biomarker validation which is essential when moving quickly. Fast Tracked does not stand alone: it frequently interacts with Priority Review and Accelerated Approval, meaning a product that is Fast Tracked can also be considered for Priority Review—which targets a six-month FDA review instead of ten months—and can be eligible for Accelerated Approval if surrogate endpoints are acceptable and confirmatory trials are planned; Fast Tracked therefore serves as a gateway that helps sponsors navigate the web of expedited pathways available at the FDA.
Fast Tracked Client Reviews 2026 Fast Tracked as a concept is administered by the FDA and was created to shorten the time between promising research and patient availability, and when a company is Fast Tracked it gains privileges like more frequent meetings and written communications with regulators, the ability to submit portions of its application on a rolling basis, and eligibility to be considered for related pathways such as Accelerated Approval or Priority Review; Fast Tracked therefore operates across the lifecycle of drug development, from pre-IND interactions through pre-NDA or pre-BLA discussions, and sponsors that secure Fast Tracked status can use that status to clarify trial design, biomarker use, and the evidence needed to demonstrate benefit without changing the safety standards for approval. Fast Tracked sits alongside other FDA expedited programs like Breakthrough Therapy designation, Accelerated Approval, and Priority Review, but Fast Tracked stands out because it can be granted earlier in development based on nonclinical evidence or a mechanistic rationale, and because it explicitly encourages ongoing FDA–sponsor dialogue, which helps reduce regulatory uncertainty; Fast Tracked has been part of the regulatory landscape for decades and has had measurable impact—12 of the novel drugs approved in 2022 had Fast Tracked status—so when people refer to being Fast Tracked they are describing a regulatory posture that can materially alter timelines and interactions, not a promise of faster approval at the expense of safety, and not a substitute for rigorous evidence but rather a structured way to reach decisions faster while still meeting statutory requirements. Order Now Fast Tracked Pros & Cons